Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in... Read more.
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improvement in progression-free survival with... Read more.
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
− Four-year Analysis Conducted by GHSG Reported ADCETRIS + ECADD Combination Improved Progression-Free Survival, Showing Superior Efficacy and Tolerable Safety... Read more.
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
CHICAGO–(BUSINESS WIRE)–ASCO Annual Meeting – Massive Bio, pioneering leader in AI-driven oncology solutions, is excited to announce the launch of... Read more.
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
– Data Support the Ongoing Phase 3 STAR-221 Study of Domvanalimab Plus Zimberelimab and Chemotherapy, Potentially the First Anti-TIGIT Combination to Market for... Read more.
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
– Differentiated Mechanism of Action of a Chimeric Degrader as Compared to Fulvestrant and Novel SERDs – – Treatment with AC699 Monotherapy Resulted in 21%... Read more.
The World’s Light Painting Masters and GAC Work Together to Create a Chinese Giant Light-Painted Dragon That Shines in Dubai for the First Time
GUANGZHOU, China–(BUSINESS WIRE)–Coinciding with the Chinese Year of the Dragon in 2024, in order to celebrate the 40th anniversary of the establish... Read more.
COPY APPROVAL Esheet # 54025820 / 5497892c
COPY APPROVAL Esheet # 54025820 / 5497892c DATELINE–(BUSINESS WIRE)–$CASH #CASH–COPY APPROVAL Esheet # 54025820 / 5497892c Contacts [email protected]... Read more.
AnalytixInsight Reports 2023 Financial Results and Provides MCTO Status Update
TORONTO–(BUSINESS WIRE)–$ALY.V #AI–AnalytixInsight Inc. (“AnalytixInsight”, or the “Company”) (TSX-V: ALY) today reports its financial... Read more.
Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against Rivian Automotive, Inc. and Certain Executives
NEW YORK–(BUSINESS WIRE)–Labaton Keller Sucharow LLP (“Labaton”) announces that, on May 31, 2024, it filed a securities class action lawsuit (the... Read more.